Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022

On October 5, 2022 Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, reported that it will present preclinical data for two of its cis-targeted immunotherapies, AB248 and AB821, at the Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, being held in Boston, Massachusetts, on November 8-12, 2022 (Press release, Asher Biotherapeutics, OCT 5, 2022, View Source [SID1234621745]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AB248, Asher Bio’s lead cis-targeted immunotherapy, is a novel CD8-targeted IL-2 mutein designed to selectively activate interleukein-2 (IL-2) signaling on CD8+ T cells over natural killer cells and regulatory T (Treg) cells. Asher Bio plans to investigate the use of AB248 in multiple solid tumor indications as monotherapy and in combination with PD(L)-1 checkpoint inhibitors and expects to initiate a Phase 1 clinical trial in the fourth quarter of 2022.

AB821 is a CD8-targeted interleukin 21 (IL-21), designed to selectively activate CD8+ T cells with an attenuated version of IL-21. Asher Bio expects to file an investigational new drug application for AB821 in the second half of 2023.

Details of the poster presentations are as follows:

Title: CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models

Session Date and Time: Friday Nov 11th, 9:00 a.m. – 9:00 p.m. ET
Location: Hall C
Abstract Number: 1092
Title: AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cells

Session Date and Time: Thursday, Nov. 10th , 9:00 a.m. – 9:00 p.m. ET
Location: Hall C
Abstract Number: 1083
Both abstracts will become available online on the SITC (Free SITC Whitepaper) conference website beginning at 8:00 a.m. ET on Monday, November 7, 2022.